[1] Zhang X, Wang Z, Tang W,et al. Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics. Hepatology,2022 ,76(2):317-329. [2] Liu Y, Zheng J, Hao J,et al. Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019. Cancer Med,2022,11(5):1310-1323. [3] Xian L, Zhao P, Chen X,et al. Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer. Cell Oncol (Dordr),2022,45(5):1019-1036. [4] 于艳龙, 刘中华, 史赢,等. 术前中性粒细胞与淋巴细胞比值和肿瘤相关因素预测肝癌患者微血管浸润. 中华肝胆外科杂志, 2019, 25(2):120-123. [5] Kim JG, Jang KM, Min GS,et al. Questionable correlation of the apparent diffusion coefficient with the histological grade and microvascular invasion in small hepatocellular carcinoma. Clin Radiol,2019,74(5):406,e19-406,e27. [6] Zhang L, Lin JB, Jia M,et al. Clinical and imaging features preoperative evaluation of histological grade and microvascular infiltration of hepatocellular carcinoma. BMC Gastroenterol,2022,22(1):369. [7] 杜品清,刘云国,胡毅,等. 肝细胞癌微血管浸润的CT和MRI影像特征及其诊断价值.肝脏, 2020, 25(2):138-141. [8] 中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版) . 中华消化外科杂志,2017,16(7): 705-720. [9] Kim BH, Lee D, Jung KW,et al. Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area. Clin Mol Hepatol,2022,28(2):242-253. [10] Chen Q, Xiao H, Gu Y,et al. Deep learning for evaluation of microvascular invasion in hepatocellular carcinoma from tumor areas of histology images. Hepatol Int,2022,16(3):590-602. [11] Buxeda A, Llinàs-Mallol L, Gimeno J,et al. Microvascular inflammation in the absence of human leukocyte antigen-donor-specific antibody and C4d: An orphan category in Banff classification with cytotoxic T and natural killer cell infiltration. Am J Transplant,2023,23(4):464-474. [12] Gu W, Tong Z. Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis. J Int Med Res,2020 ,48(8):300060520946872. [13] Oh JG, Choi SY, Lee MH,et al. Differentiation of hepatic abscess from metastasis on contrast-enhanced dynamic computed tomography in patients with a history of extrahepatic malignancy: emphasis on dynamic change of arterial rim enhancemen, Abdom Radiol (NY),2019,44(2):529-538. [14] 柴梦琪, 李娜, 吴英宁,等. 钆塞酸二钠增强磁共振成像与CT增强扫描对肝细胞癌的诊断价值. 实用放射学杂志,2020,36(7):1077-1080. [15] Ji GW, Zhu FP, Xu Q,et al. Radiomic features at contrast-enhanced CT predict recurrence in early stage hepatocellular carcinoma: A multi-institutional Study. Radiology,2020 ,294(3):568-579. [16] 张艳, 刘影. 普美显动态增强MRI和动态增强CT对肝细胞肝癌血供的评估与病理对照分析. 临床放射学杂志,2021,40(7):1334-1339. [17] Kim TH, Yoon JH, Lee JM,et al. Emerging role of hepatobiliary magnetic resonance contrast media and contrast-enhanced ultrasound for noninvasive diagnosis of hepatocellular carcinoma: Emphasis on recent updates in major guidelines, Korean J Radiol,2019,20(6):863-879. [18] Ham JH, Yu JS, Choi JM,et al. Corona enhancement can substitute enhancing capsule in the imaging diagnosis of small (≤3cm) HCCs on gadoxetic acid-enhanced MRI. Eur Radiol,2021,31(11):8628-8637. [19] Corvino A, Sandomenico F, Setola SV,et al. Morphological and dynamic evaluation of complex cystic focal liver lesions by contrast-enhanced ultrasound: current state of the art. J Ultrasound,2019,22(3):251-259. [20] 陈霞,李文柱,陈旺生,等.多模态MRI术前诊断肝细胞癌微血管浸润应用进展.中国医学影像技术, 2019,35(2):294-297. |